|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
De Grève J, Van Meerbeeck J, Vansteenkiste
JF, Decoster L, Meert AP, Vuylsteke P, Focan C, Canon JL, Humblet
Y, Berchem G, et al: Prospective evaluation of first-line erlotinib
in advanced non-small cell lung cancer (NSCLC) carrying an
activating EGFR mutation: A multicenter academic phase II study in
Caucasian patients (FIELT). PLoS One. 11:e01475992016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kazandjian D, Blumenthal GM, Yuan W, He K,
Keegan P and Pazdur R: FDA Approval of gefitinib for the treatment
of patients with metastatic EGFR mutation-positive non-small cell
lung cancer. Clin Cancer Res. 22:1307–1312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yang JC, Hirsh V, Schuler M, Yamamoto N,
OByrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey
D, et al: Symptom control and quality of life in LUX-Lung 3: A
phase III study of afatinib or cisplatin/pemetrexed in patients
with advanced lung adenocarcinoma with EGFR mutations. J Clin
Oncol. 31:3342–3350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó
L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, et al:
Crizotinib versus chemotherapy in advanced ALK-positive lung
cancer. N Engl J Med. 368:2385–2394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E,
Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, et al:
Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J
Med. 370:1189–1197. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ou SH, Ahn JS, De Petris L, Govindan R,
Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, et
al: Alectinib in crizotinib-refractory ALK-rearranged
non-small-cell lung cancer: A phase II global study. J Clin Oncol.
34:661–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garon EB, Leighl NB, Rizvi NA,
Blumenschein GR, Balmanoukian AS, Eder JP, Goldman JW, Hui R, Soria
JC, Gangadhar TC, et al: Safety and clinical activity of MK-3475 in
previously treated patients with non-small cell lung cancer. J Clin
Oncol. 32:80202014.
|
|
10
|
Casaluce F, Sgambato A, Sacco PC,
Palazzolo G, Maione P, Rossi A, Ciardiello F and Gridelli C:
Emerging drugs targeting PD-1 and PD-L1: Reality or hope? Expert
Opin Emerg Drugs. 19:557–569. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tatarelli C, Linnenbach A, Mimori K and
Croce CM: Characterization of the human TESTIN gene localized in
the FRA7G region at 7q31.2. Genomics. 68:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tobias ES, Hurlstone AF, MacKenzie E,
McFarlane R and Black DM: The TES gene at 7q31.1 is methylated in
tumours and encodes a novel growth-suppressing LIM domain protein.
Oncogene. 20:2844–2853. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mruk DD and Cheng CY: Rat and mouse
testicular testin is different from the human tumor suppressor gene
TESTIN (Tes): Authors response to the letter of Dr. S. Kapoor.
Spermatogenesis. 2:3052012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Drusco A, Zanesi N, Roldo C, Trapasso F,
Farber JL, Fong LY and Croce CM: Knockout mice reveal a tumor
suppressor function for Testin. Proc Natl Acad Sci USA.
102:10947–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chêne L, Giroud C, Desgrandchamps F,
Boccon-Gibod L, Cussenot O, Berthon P and Latil A: Extensive
analysis of the 7q31 region in human prostate tumors supports TES
as the best candidate tumor suppressor gene. Int J Cancer.
111:798–804. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mueller W, Nutt CL, Ehrich M,
Riemenschneider MJ, von Deimling A, van den Boom D and Louis DN:
Downregulation of RUNX3 and TES by hypermethylation in
glioblastoma. Oncogene. 26:583–593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gu Z, Ding G, Liang K, Zhang H, Guo G,
Zhang L and Cui J: TESTIN suppresses tumor growth and invasion via
manipulating cell cycle progression in endometrial carcinoma. Med
Sci Monit. 20:980–987. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qiu H, Zhu J, Yuan C, Yan S, Yang Q and
Kong B: Frequent hypermethylation and loss of heterozygosity of the
testis derived transcript gene in ovarian cancer. Cancer Sci.
101:1255–1260. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sarti M, Sevignani C, Calin GA, Aqeilan R,
Shimizu M, Pentimalli F, Picchio MC, Godwin A, Rosenberg A, Drusco
A, et al: Adenoviral transduction of Testin gene into breast and
uterine cancer cell lines promotes apoptosis and tumor reduction in
vivo. Clin Cancer. 11:806–813. 2005.
|
|
20
|
Ohkouchi S, Kawamoto N, Koga M, Sakanashi
F, Shichijo S, Saijo Y, Nukiwa T, Itoh K and Yamada A:
Identification of a CTL-directed epitope encoded by an intron of
the putative tumor suppressor gene Testin of the common fragile
site 7G region: A peptide vaccine candidate for HLA-B52+
and HLA-62+ cancer patients. Eur J Immunol.
33:2964–2973. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Griffith E: Using RNA interference to
knock down the adhesion protein TES. Methods Mol Biol. 370:97–108.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu J, Li X, Kong X, Moran MS, Su P,
Haffty BG and Yang Q: Testin is a tumor suppressor and prognostic
marker in breast cancer. Cancer Sci. 103:2092–2101. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Long JG, Zhang CQ and Zhao L: Expression
of Testin in human colorectal carcinoma and its clinical
significance. Chin Oncol. 19:428–432. 2009.(In Chinese).
|
|
24
|
Yu H, Ling TS, Shu QW and Shi RH: The
association of TESTIN and Caspase-3 protein expressions with
clinicopathological features and prognosis of esophageal squamous
cell carcinoma. Chin J Dig. 30:47–52. 2010.
|
|
25
|
Weeks RJ, Ludgate JL, LeMée G and Morison
IM: TESTIN induces rapid death and suppresses proliferation in
childhood B acute lymphoblastic leukaemia cells. PLoS One.
11:e01513412016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong R, Pu H, Wang Y, Yu J, Lian K and Mao
C: TESTIN was commonly hypermethylated and involved in the
epithelial-mesenchymal transition of endometrial cancer. APMIS.
123:394–400. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang W, Weng DS, Pan ZZ, Pan K, Ding PR,
Zhou J, Wang H, Zhang HK, Li JJ and Xia JC: Expression and clinical
significance of TESTIN in primary gastric cancer. Ai Zheng.
27:984–988. 2008.(In Chinese). PubMed/NCBI
|
|
28
|
Weeks RJ, Kees UR, Song S and Morison IM:
Silencing of TESTIN by dense biallelic promoter methylation is the
most common molecular event in childhood acute lymphoblastic
leukaemia. Mol Cancer. 9:1632010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhong Z, Zhang F and Yin SC: Effects of
TESTIN gene expression on proliferation and migration of the 5-8F
nasopharyngeal carcinoma cell line. Asian Pac J Cancer Prev.
16:2555–2559. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sarti M, Pinton S, Limoni C, Carbone GM,
Pagani O, Cavalli F and Catapano CV: Differential expression of
testin and survivin in breast cancer subtypes. Oncol Rep.
30:824–832. 2013.PubMed/NCBI
|
|
31
|
Garvalov BK, Higgins TE, Sutherland JD,
Zettl M, Scaplehorn N, Köcher T, Piddini E, Griffiths G and Way M:
The conformational state of Tes regulates its zyxin-dependent
recruitment to focal adhesions. J Cell Biol. 161:33–39. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Coutts AS, MacKenzie E, Griffith E and
Black DM: TES is a novel focal adhesion protein with a role in cell
spreading. J Cell Sci. 116:897–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Griffith E, Coutts AS and Black DM: RNAi
knockdown of the focal adhesion protein TES reveals its role in
actin stress fibre organisation. Cell Motil Cytoskeleton.
60:140–152. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Freyd G, Kim SK and Horvitz HR: Novel
cysteine-rich motif and homeodomain in the product of the
Caenorhabditis elegans cell lineage gene lin-11. Nature.
344:876–879. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Karlsson O, Thor S, Norberg T, Ohlsson H
and Edlund T: Insulin gene enhancer binding protein Isl-1 is a
member of a novel class of proteins containing both a homeo- and a
Cys-His domain. Nature. 344:879–882. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Michelsen JW, Sewell AK, Louis HA, Olsen
JI, Davis DR, Winge DR and Beckerle MC: Mutational analysis of the
metal sites in an LIM domain. J Biol Chem. 269:11108–11113.
1994.PubMed/NCBI
|
|
37
|
Dawid IB, Toyama R and Taira M: LIM domain
proteins. C R Acad Sci III. 318:295–306. 1995.PubMed/NCBI
|
|
38
|
Weis SM and Cheresh DA: Tumor
angiogenesis: Molecular pathways and therapeutic targets. Nat Med.
17:1359–1370. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stuart-Harris R, Caldas C, Pinder SE and
Pharoah P: Proliferation markers and survival in early breast
cancer: A systematic review and meta-analysis of 85 studies in
32,825 patients. Breast. 17:323–334. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
He X, Chen Z, Fu T, Jin X, Yu T, Liang Y,
Zhao X and Huang L: Ki-67 is a valuable prognostic predictor of
lymphoma but its utility varies in lymphoma subtypes: Evidence from
a systematic meta-analysis. BMC Cancer. 14:1532014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
van Velthuysen ML, Groen EJ, van der Noort
V, van de Pol A, Tesselaar ME and Korse CM: Grading of
neuroendocrine neoplasms: Mitoses and Ki-67 are both essential.
Neuroendocrinology. 100:221–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Berghoff AS, Ilhan-Mutlu A, Wöhrer A,
Hackl M, Widhalm G, Hainfellner JA, Dieckmann K, Melchardt T, Dome
B, Heinzl H, et al: Prognostic significance of Ki67 proliferation
index, HIF1 alpha index and microvascular density in patients with
non-small cell lung cancer brain metastases. Strahlenther Onkol.
190:676–685. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Del Gobbo A, Pellegrinelli A, Gaudioso G,
Castellani M, Marino F Zito, Franco R, Palleschi A, Nosotti M,
Bosari S, Vaira V, et al: Analysis of NSCLC tumour heterogeneity,
proliferative and 18F-FDG PET indices reveals Ki67 prognostic role
in adenocarcinomas. Histopathology. 68:746–751. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ji Y, Zheng M, Ye S, Chen J and Chen Y:
PTEN and Ki67 expression is associated with clinicopathologic
features of non-small cell lung cancer. J Biomed Res. 28:462–467.
2014.PubMed/NCBI
|
